Genelux Corporation is a clinical-stage biopharmaceutical company that develops oncolytic viral immunotherapies to treat aggressive or difficult-to-treat solid tumors, with Olvi-Vec as its leading candidate for treating ovarian cancer and non-small-cell lung cancer. Additionally, the company is making progress in developing V2ACT Immunotherapy for pancreatic cancer and V-VET1 for hematologic and solid cancer. The company is based in Westlake Village, California and was founded in 2001.